Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Cash from Financing Activities (2023 - 2025)

Mangoceuticals' Cash from Financing Activities history spans 3 years, with the latest figure at $1.6 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 116.21% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $6.3 million, up 50.03%, while the annual FY2024 figure was $4.1 million, 41.5% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $1.6 million at Mangoceuticals, up from $1.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $5.0 million in Q1 2023 and bottomed at $267500.0 in Q1 2024.
  • The 3-year median for Cash from Financing Activities is $1.2 million (2023), against an average of $1.6 million.
  • The largest annual shift saw Cash from Financing Activities crashed 94.65% in 2024 before it soared 754.21% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $1.2 million in 2023, then dropped by 6.46% to $1.1 million in 2024, then skyrocketed by 44.46% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Cash from Financing Activities are $1.6 million (Q3 2025), $1.3 million (Q2 2025), and $2.3 million (Q1 2025).